US researchers have revealed(link is external) the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them.
The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.
“This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.
“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.
The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.
Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.
“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.
Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.
In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.
Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.
The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.
The Latest on: Immunotherapies
[google_news title=”” keyword=”Immunotherapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapies
- Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updateson May 9, 2024 at 3:01 pm
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus ...
- Scientists Develop AI-Powered Model to Enhance Cancer Immunotherapieson May 9, 2024 at 4:20 am
Scientists at Ludwig Cancer Research With the use of AI, have developed a predictive model that can identify the cancer-killing immune cells that have the highest potential to be used in ...
- Meet the pioneer of cancer immunotherapieson May 9, 2024 at 3:33 am
Please enter your username and password below, if you are not yet a member of BioTechniques remember you can register for free.
- Immune cell discovery ‘could lead to personalised treatment for breast cancer’on May 7, 2024 at 10:32 pm
Researchers have developed a tool to identify these anti-cancer cells which could lead to improved, personalised immunotherapies, they say. Our research has revealed that the immune response to cancer ...
- AI predicts tumor-killing cells with high accuracyon May 7, 2024 at 4:23 pm
Using artificial intelligence, scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.
- Precision medicine tool predicts breast cancer immunotherapy responseon May 6, 2024 at 10:30 am
New InteractPrint tool analyzes how breast cancer epithelial cells impact cancer-immune interactions, enabling prediction of immune checkpoint inhibition response.
- New approach for developing cancer vaccines could make immunotherapies more effective in acute myeloid leukemiaon May 3, 2024 at 12:13 pm
Acute myeloid leukemia (AML) is a type of blood cancer that forms in the soft marrow of the bones, typically attacking cells that would otherwise form the key component of the body's immunodefense ...
- Immune cell discovery ‘could lead to personalised treatment for breast cancer’on May 1, 2024 at 5:00 pm
Researchers have developed a tool to identify these anti-cancer cells which could lead to improved, personalised immunotherapies, they say. Our research has revealed that the immune response to ...
- Adjuvant Immunotherapies as a Novel Approach to Bacterial Infectionson April 10, 2024 at 5:00 pm
Here, we discuss the potential of adjuvant immunotherapies to selectively stimulate protective immune responses as a treatment option for bacterial infections. In order to elicit appropriate ...
- Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024on April 8, 2024 at 11:59 pm
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies ...
via Bing News